Drug firm Suven Life Sciences today reported a 56 per cent rise in standalone net profit to Rs 62.51 crore for the March quarter. It had posted a net profit of Rs 40.06 crore for the corresponding period of the previous fiscal, Suven Life Sciences said in a filing to BSE.
Its standalone revenue from operations rose to Rs 213.72 crore for the fourth quarter of 2017-18. The revenue was Rs 180.14 crore in Q4 of 2016-17. For the entire fiscal ended March this year, the company posted a net profit of Rs 158.42 crore as against Rs 123.47 crore in the previous fiscal. Suven’s standalone total revenue from operations rose to Rs 625.25 crore for 2017-18. It was Rs 544.47 crore in 2016-17. The company’s stock was up 4.65 per cent at Rs 190.30 on BSE.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.